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Abstract
Background: During and following myocardial ischemia, glucose oxidation rates are low and fatty acids dominate as a 
source of oxidative metabolism. This metabolic phenotype is associated with contractile dysfunction during 
reperfusion. To determine the mechanism of this reliance on fatty acid oxidation as a source of ATP generation, a 
functional proteomics approach was utilized.
Results: 2-D gel electrophoresis of mitochondria from working rat hearts subjected to 25 minutes of global no flow 
ischemia followed by 40 minutes of aerobic reperfusion identified 32 changes in protein abundance compared to 
aerobic controls. Of the five proteins with the greatest change in abundance, two were increased (long chain acyl-
coenzyme A dehydrogenase (48 ± 1 versus 39 ± 3 arbitrary units, n = 3, P < 0.05) and α subunit of ATP synthase (189 ± 
15 versus 113 ± 23 arbitrary units, n = 3, P < 0.05)), while two were decreased (24 kDa subunit of NADH-ubiquinone 
oxidoreductase (94 ± 7 versus 127 ± 9 arbitrary units, n = 3, P < 0.05) and D subunit of ATP synthase (230 ± 11 versus 
368 ± 47 arbitrary units, n = 3, P < 05)). Two forms of pyruvate dehydrogenase βE1 subunit, the rate-limiting enzyme for 
glucose oxidation, were also identified. The protein level of the more acidic form of pyruvate dehydrogenase was 
reduced during reperfusion (37 ± 4 versus 56 ± 7 arbitrary units, n = 3, P < 05), while the more basic form remained 
unchanged. The more acidic isoform was found to be O-palmitoylated, while both isoforms exhibited ischemia/
reperfusion-induced phosphorylation. In silico analysis identified the putative kinases as the insulin receptor kinase for 
the more basic form and protein kinase Cζ or protein kinase A for the more acidic form. These modifications of 
pyruvate dehydrogenase are associated with a 35% decrease in glucose oxidation during reperfusion.
Conclusions: Cardiac ischemia/reperfusion induces significant changes to a number of metabolic proteins of the 
mitochondrial proteome. In particular, ischemia/reperfusion induced the post-translational modification of pyruvate 
dehydrogenase, the rate-limiting step of glucose oxidation, which is associated with a 35% decrease in glucose 
oxidation during reperfusion. Therefore these post-translational modifications may have important implications in the 
regulation of myocardial energy metabolism.
Background
Myocardial ischemia results from the transient blockage
of the systemic circulation due to a number of mecha-
nisms including atherosclerosis, embolism and surgical
procedures resulting in a mismatch between the oxygen
requirement of the heart and the oxygen supplied via the
coronary circulation. Although many studies have exam-
ined ischemia/reperfusion (I/R) injury and possible ther-
apeutic strategies, the exact molecular and cellular
mechanisms continue to be elusive and it remains devas-
tating cause of morbidity and mortality worldwide. Pro-
teomics provides a powerful experimental approach for
the observing the global changes in protein abundance
and has recently been used to identify novel post-transla-
tional modifications (PTMs) of these proteins [1,2]. Uti-
lizing this approach, several studies have examined the I/
R and preconditioning induced changes of the heart pro-
teome [3-8]. Interestingly, many of the identified proteins
have important functions in cardiac energy metabolism,
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which suggests an important role for alterations in
metabolism as a contributor to the pathophysiology of I/
R injury.
Under normal aerobic conditions, the heart preferen-
tially metabolizes fatty acids, which contribute between
60% and 80% of the required ATP [9]. However, during
reperfusion fatty acid oxidation quickly recovers, at the
expense of glucose oxidation, and predominates as the
main source of mitochondrial oxidative metabolism [10-
12]. This is believed to be due to the exposure of the heart
to high levels of circulating fatty acids, as well as to sub-
cellular changes in the control of myocardial fatty acid
oxidation [13,14]. In addition, anaerobic glycolysis
increases and becomes an important source of ATP for
the maintenance of ion gradients in the cardiomyocyte
during ischemia [15]. However, if the pyruvate from glyc-
olysis is not subsequently oxidized, and glycolytically
derived ATP is hydrolyzed, there is a net production of
both lactate and protons due to the uncoupling of glycol-
ysis from glucose oxidation [16,17]. The protons pro-
duced are a major contributor to the intracellular acidosis
that is associated with ischemia. This acidosis can lead to
adverse events, including accelerated sarcolemmal Na+/
H+ exchange resulting in intracellular Na+ and Ca2+ over-
load [18], the initiation of cardiac arrhythmias [19,20]
and a decreased response of contractile proteins to Ca2+
[19]. If the pyruvate from glycolysis is aerobically metabo-
lized (i.e. glucose oxidation), then lactate and protons are
not produced, leading to improved functional recovery
during reperfusion [21].
The majority of the heart's essential catabolic machin-
ery resides in the mitochondria. Despite the fact that the
human heart mitochondrial proteome has been resolved
and approximately 50% of the identified proteins are
involved in metabolism [22], only a few studies has spe-
cifically examined the I/R induced global changes in the
m it oc ho ndria l pr ot eo me  [7, 8] . In t his  s t udy we  used a
proteomics approach to observe the I/R induced changes
in abundance of mitochondrial proteins, one of which
was identified as the βE1 subunit of pyruvate dehydroge-
nase (PDHβE1), a key regulatory enzyme that directly
modulates the rates of glucose oxidation. We subse-
quently demonstrated that this subunit contains novel
post-translational modification (PTMs). These PTMs
may lead to the changes in enzyme activity, and are there-
fore potentially sites regulating myocardial energy metab-
olism during ischemia and reperfusion.
Methods
Animals
The University of Alberta adheres to the principles for
biomedical research involving animals developed by the
Council for International Organizations of Medical Sci-
ences and complies with Canadian Council of Animal
Care guidelines.
Isolated working rat hearts
Rat hearts were cannulated for isolated working heart
perfusions as described previously [23]. 9 biological repli-
cates per group were utilized for cardiac function with 6
of these biological replicates utilized for measurement of
myocardial metabolism and 3 biological replicates uti-
lized for subsequent 2-D PAGE analysis. In brief, male
Sprague-Dawley rats (0.25-0.3 Kg) were anesthetized
with sodium pentobarbital (60 mg/Kg i.p.), and the hearts
were quickly excised, and the aorta and left atria cannu-
lated. Oxygenated Krebs-Henseleit solution containing
1.2 mM palmitate bound to 3% BSA, 5 mM glucose, and
100 μU/mL insulin was delivered to the left atrium at a
preload pressure of 11.5 mmHg. One series of hearts was
perfused for 35 min of aerobic perfusion, 25 min of global
no-flow ischemia, followed by 40 min of aerobic reperfu-
sion. This time of ischemia results in myocardial stunning
without significant myocardial necrosis and was chosen
to result in approximately 30% recovery of mechanical
function during reperfusion. Another series of hearts
underwent 100 min of aerobic perfusion to serve as a
time-matched aerobic control group. These hearts were
immediately removed after the perfusion protocol and
mitochondria were isolated using a differential centrifu-
gation protocol previously described [24]. Cardiac work
was calculated as the product of aortic systolic pressure,
measured by a Gould P21 pressure transducer (Harvard
Apparatus) connected to the aortic outflow line, and car-
diac output, measured with a T206 ultrasonic flow probe
(Transonic Systems Inc.) in the preload line.
Measurement of glucose and palmitate oxidation
An additional series of hearts were perfused using the I/R
protocol to measure rates of myocardial energy metabo-
lism. Glucose oxidation and palmitate oxidation were
m e a s u r e d  b y  p e r f u s i n g  h e a r t s  w i t h  [ U - 14C]glucose or
[9,10-3H]palmitate, respectively, with quantitative mea-
surement of 14CO2 or 3H2O production, as described pre-
viously [23].
Isolation of Mitochondria
After the perfusions, the hearts were quickly rinsed in
ice-cold 225 mM mannitol, 75 mM sucrose, 1 mM EGTA,
10 mM Tris, pH 7.5 (MSE buffer). The atria were
removed and the ventricles minced. A 20% (w/v) tissue
suspension in MSE buffer was adjusted between pH 7.4 to
7.5. The suspension was homogenized with a Polytron
homogenizer for two 10-second periods. The homoge-
nate was centrifuged at 480 × g for 5 min, and the super-
natant (S1) was filtered through cheese cloth and
centrifuged at 10,000 × g for 30 min. The pellet (Pi), fromFolmes et al. Proteome Science 2010, 8:38
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the 480 × g spin, was suspended in MSE buffer and
homogenized again under the same settings and centri-
fuged at 480 × g for 5 min. The supernatant (S2) was fil-
tered through cheesecloth and was centrifuged at 10,000
× g for 30 min. The S2 pellet was combined with the S1
pellet suspended using MSE buffer and centrifuged at
10,000 × g for 30 min. The resulting pelleted mitochon-
dria (S3) was suspended in a urea solution in a 1:2 (w/v)
ratio and used for 2D electrophoresis [24]. Mitochondrial
purity was assessed by Western blotting for the cytosolic
marker, GAPDH (Abcam) and mitochondrial marker,
mitochondrial creatine kinase (mtCK, Abcam).
Preparation of mitochondria extracts
Protein samples for 2-D electrophoresis were prepared at
room temperature by mixing one part of the mitochon-
dria pellet with two parts (w:v) of rehydration buffer (8
mol/L urea, 4% CHAPS, 10 mmol/L DTT, 0.2% Bio-Lytes
3/10 [BioRad]). Samples were sonicated twice for 5 s and
centrifuged for 10 min at 10,000 g at room temperature to
remove any insoluble particles. Protein content of the
mitochondrial extract in rehydration buffer was mea-
sured using the BioRad protein assay.
Two-dimensional polyacrylamide gel electrophoresis
400 μg of mitochondria extract protein was originally
applied to 11 cm immobilized pH gradient strip with lin-
ear pH gradient from 3 to 10 (IPG, Biorad) and equili-
brated for 16-18 hr at 20°C in rehydration buffer, however
we subsequent utilized a pH gradient of 5 to 8 to increase
the resolution and separation of protein spots. These
conditions have been previously validated to result in
even protein loading [25]. For isoelectrofocusing, the Bio-
Rad Protean isoelectrofocusing cell was used with the
conditions described previously [26]. The second dimen-
sion of electrophoresis was carried out using 8-16% acryl-
amide Criterion precast gradient gels (BioRad). To
minimize variations in resolving proteins during the sec-
ond dimension run, all gels were run simultaneously
using a Criterion Dodeca Cell (BioRad). After separation,
proteins were detected using Coomassie Brilliant Blue R-
250 (BioRad). Developed gels were scanned using a cali-
brated GS-800 densitometer (BioRad). Quantitative anal-
ysis of spot intensity from 2-D electrophoresis was
measured using PDQuest 7.1 software (BioRad). Only
protein spots with a relative intensity between 10-100
arbitrary units were considered for analysis. Using these
criteria for protein resolution and staining, we were able
to obtain high reproducibility to analyze both a single
protein from the same sample run in different gels and for
a specific protein spot from different heart samples. 3
analytical replicates were utilized for 2-D PAGE and sub-
sequent mass spectrometry identification.
Mass spectrometry
Protein spots were manually excised from the 2-D gel.
Subsequently, in-gel trypic digests were analyzed using a
Bruker Ultraflex TOF/TOF mass spectrometer. Digests
were applied to an AnchorChip plate (Bruker) as previ-
ously described [27]. Mass spectra and tandem mass
spectra were then obtained in an automated fashion
using the AutoXecute function. Typically 100 shots were
accumulated to generate a peptide mass fingerprint. The
5 most intense peaks were then selected to have MS/MS
performed where 400 shots on average were used to gen-
erate a MS/MS profile (3 analytical replicates). Peaklist
generation and peak picking was performed using Flex-
analysis 2.2 SNAP (sophisticated numerical annotation
procedure), with default setting for peaklist generation.
For PMF data the S/N threshold = 6, resolution >6000,
they were externally calibrated using 8 peptides with m/z
ranging from 757.39 to 3147.47 and tryptic autolytic pep-
tides are excluded. Acceptance criteria for MS/MS was at
least 2 matching peptides with a score P < 05. The resul-
tant MS or MS/MS data was searched using the MAS-
COT version 2.2 http://www.matrixscience.com search
engine against NCBInr (2007) and Swiss-Prot (2007)
databases. Specified 68,229 protein sequences from
NCBInr for Rattus Norvegicus was used for identification
of the proteins. The Mowse scoring algorithm was used
for justification of protein identification [28].
Calculation of the theoretical masses of PDHβ peptides 
generated by the enzymatic cleavage
PeptideMass http://au.expasy.org/tools/peptide-
mass.html was used to predict the mass of trypsin-
digested peptides from the sequence of PDHβ. For calcu-
l a t i o n  o f  t h e o r e t i c a l  p e p t i d e  m a s s e s  w e  a s s u m e d :  1 )
incomplete protein digestion (1 missed cleavage level)
and ± 0.2 Da error windows on experimental peptide
mass values and for MS/MS fragment ion mass values, 2)
mandatory alkylation and reduction of cysteines with
iodoacteamide, and 3) variable oxidation of methionine.
Only peptides bigger than 500 Da were considered.
Examination of experimental peptide mass fingerprinting 
for post-translational modifications (PTMs)
FindMod tool (2007) was used to find potential PTMs
http://au.expasy.org/tools/findmod/ in the experimental
peptides of PDHβ. 22 types of PTMs were considered
with the assumption that up to 3 PTM in one peptide can
exists.
Chemical verification of O-palmitolyation
Experimental peptides with identified (in silico) palmi-
toylation were incubated with 0.1 M KOH for 4 hr at
room temperature [29] and analysed by MALDI TOF-
TOF.Folmes et al. Proteome Science 2010, 8:38
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Verification of phosphorylation by dephosphorylation of 
peptide with alkaline phosphatase
Experimental peptides with identified (In silico) phospho-
rylation were incubated with 0.5 unit of alkaline phospa-
tase in 50 mM bicarbonate solution for 120 min at 30°C
and analyzed by MALDI TOF-TOF [30].
Prediction of kinases that phosphorylate the βE1 PDH
PDH phosphorylating kinases were predicted using phos-
phorylation consensus sequences identified with Scansite
http://scansite.mit.edu/ and NetPhosK 1.0 Sever http://
www.cbs.dtu.dk/services/NetPhosK/.
Western blotting
Protein (30 μg) from heart homogenate or from mito-
chondria preparation was separated using 12% SDS-
PAGE and transferred to a PVDF membrane (Bio-Rad).
Glyceraldehydes 3-phosphate dehydrogenase (GAPDH)
was identified using mouse monoclonal anti-GAPDH
antibody (Abcam). Mitochondrial creatine kinase (mtCK)
was identified with rabbit polyclonal anti-mtCK antibody
(Abcam). Band densities were measured using Versa Doc
5000 and Quantity One 4.6 software (Bio-Rad).
Statistical analysis
Data are shown as mean ± SEM. Analysis of functional
data, the protein spots in the 2-D electrophoresis experi-
ments and metabolic data were performed using
unpaired t-tests. A value of p < 0.05 was considered sta-
tistically significant.
Results
Cardiac function in hearts subjected to aerobic perfusion 
and I/R
Hearts were perfused either for 100 min aerobically, or
for 35 min aerobically followed by 25 min of global isch-
emia and 40 min of reperfusion (Figure 1A). The func-
tional recovery of hearts subjected to I/R was
significantly reduced compared to hearts aerobically per-
fused for 100 min (Figure 1B). Glucose oxidation rates
were decreased by 35% in reperfused hearts compared to
the average glucose oxidation rates in time-matched aer-
obic control hearts (Figure 1C). Despite this reduction in
glucose oxidation rates, palmitate oxidation rates did not
differ between the I/R group and the aerobic controls
(Figure 1D).
2-D Electrophoresis and identification of proteins
The mitochondrial isolation resulted in a similar yield of
mitochondria (97 ± 8 and 102 ± 8 mg mitochondria/g wet
heart weight) with enriched expression of mtCK and free
of contamination by cytosolic GAPDH (Figure 2A). 2-D
PAGE identified 32 I/R-induced changes in protein levels
out of approximately 260 protein spots observed in all of
the gels and we chose to identify the five spots with the
greatest change in abundance (Figure 2B, C and Table 1).
Mass spectrometry analysis of all five protein spots gave
only one protein hit above the threshold for each search.
The high Moswe scores show high level of accuracy for
each identification (Table 1). Two of these protein abun-
dances were increased with I/R and were identified as
long chain acyl-coenzyme A dehydrogenase and ATP
synthase (α subunit). Three of these protein abundances
were decreased with I/R and were identified as NADH-
ubiquinone oxidoreductase (24 kDa subunit), ATP syn-
thase (D subunit) and PDH (βE1 subunit). In addition, the
protein spot adjacent to spot 2 was also identified as
PDHβE1 (Table 2). For the remainder of this study we con-
centrated on post-translational changes induced in PDH
due to the importance of this enzyme in the regulation of
myocardial glucose oxidation. Both aerobic and I/R
groups expressed two molecular forms of PDHβE1 (which
we identified as a more acidic form and more basic form
Figure 1 Ischemia and reperfusion reduced cardiac work com-
pared to aerobic control isolated working hearts. (A) Experimental 
protocol of hearts subjected to I/R. Arrow indicates when the mito-
chondrial isolation began. (B) Mechanical function of the heart after I/
R injury. (C) Rates of glucose oxidation in isolated working rat hearts 
subjected to aerobic perfusion or I/R. (D) Rates of palmitate oxidation 
in isolated working rat hearts subjected to aerobic perfusion or I/R. Val-
ues represent the mean ± SEM of 9 hearts per group for mechanical 
function and 6 hearts per group for metabolic rates.* represents P < 
0.05, significantly different from aerobic value.Folmes et al. Proteome Science 2010, 8:38
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based on their isoelectric point) but only the protein level
of the more acidic form was decreased in I/R (Figure 3B).
Protein mass fingerprints (PMFs) and modifications of PDH
Proteins were excised from the gels and subjected to
trypsin digestion followed by mass spectrometry analysis
to produce PMFs of both the more acidic and more basic
form of the βE1 subunit of PDH (Figure 4A). Comparison
of trypsin digested peptides of PDHβE1  from control
hearts using the FindMod tool showed that the more
acidic form is O-palmitoylated (peptide 1493.486 Da, Fig-
ure 4A and 4B). This unique PTM was confirmed by
KOH treatment of the peptides (Figure 4A), which led to
the disappearance of the O-palmitoylated peptide and the
appearance of a new peptide (1240.931 Da).
Upon comparison of the PMFs from the more acidic
form of PDHβE1 from the aerobic and I/R hearts, two new
peptides with masses 984.579 Da and 2397.998 Da were
detected as being putative phosphorylated peptides (Fig-
ure 5). However upon treatment with alkaline phos-
phatase, only the smaller peptide was removed (Figure 5).
Comparison of the PMFs of the more basic form of
PDHβE1 from the aerobic and I/R hearts with the Find
Mod tool, detected that I/R triggers phosphorylation of
the more basic form (peptide 1922.068, Figure 6A and
6B). This peptide peak disappeared after treatment with
alkaline phosphatase (Figure 6A). In addition, the isoelec-
tric point of the more basic form of PDHβE1  was
decreased in I/R hearts (Figure 7B), further supporting
the theory that this peptide was phosphorylated.
Identification of putative phosphorylation sites and 
kinases
Phosphorylation sites were determined by examining the
sizes of trypsin digested protein fragments with the Find-
Mod tool, the kinases were determined using Scansite
and the NetPhosK 1.0 Sever. Using this analysis we identi-
fied Ser-16 of the more acidic PDHβE1 to be a possible site
of phosphorylation with the putative kinase being protein
kinase Cζ (PKCζ) or protein kinase A (PKA) (Table 3). For
the more basic PDHβE1 we identified Tyr-132 as a possible
site of phosphorylation with the putative kinase being the
insulin receptor kinase (Table 3).
Discussion
Although there are several reports describing the mito-
chondrial proteome, only two previous studies have
attempted to provide a picture of more global changes in
protein abundance induced by I/R [7,8]. Using a func-
tional proteomics approach we identified 32 protein
spots, which are either up or down regulated by I/R. We
focused on the proteins with the largest changes in abun-
dance, which all corresponded to proteins with metabolic
functions. The proteins with an increase in abundance
included long chain acyl-coenzyme A dehydrogenase and
ATP synthase (α subunit), while proteins with a decrease
in abundance included NADH-ubiquinone oxi-
doreductase (24 kDa subunit), ATP synthase (D subunit)
and PDHβE1. Due to the identification of two protein
spots corresponding to PDHβE and the critical role PDH
plays in the regulation of myocardial glucose oxidation,
we endeavored to better characterize the two molecular
forms of PDHβE1. The major difference between the two
forms of PDHβE1 is a novel O-palmitoylation PTM to the
more acidic form of PDHβE1. In addition, I/R triggered
phosphorylation of both forms of PDHβE1 with in silico
methods identifying insulin receptor kinase and PKCζ or
PKA as the putative kinases the more basic form and acid
form respectively.
The mitochondrial PDH complex catalyzes the decar-
boxylation of pyruvate to acetyl-CoA, and consists of
multiple copies of three enzymes (E1 (pyruvate dehydro-
genase), E2 (dihydrolipoyl transacetylase) and E3 (dihy-
Figure 2 2-D electrophoresis identified five cardiac mitochondri-
al proteins that are modified following ischemia and reperfusion. 
(A) Western blots for GAPDH and mtCK to assess the purity of the mi-
tochondrial preparation from aerobic hearts. (B) Representative 2-D 
electrophoresis of heart mitochondria indicating spots picked for iden-
tification. (C) Quantification of spots and representative gels. Values 
represent the mean ± SEM of 3 hearts per group. * represents P < 0.05, 
significantly different from aerobic value.
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drolipoyl dehydrogenase), with the E1 being a tetramer
consisting of 2α and 2β subunits. This complex is regu-
lated at multiple levels including allosterically by the sub-
strates and products of the reaction [31] and due to
phosphorylation/dephosphorylation of theα chains by
the PDK and PDP [32]. Although extensive work has been
performed correlating phosphorylation of PDH by the
PDKs with activity and pyruvate flux [32], to our knowl-
edge no one has previously reported phosphorylation of
PDHβE1. The present study identified novel phosphoryla-
t i o n  e v e n t s  o n  P D H βE1 that may account for the 35%
decrease in glucose oxidation during reperfusion, and
sustain inactivation of PDH [33,34]. However it is not
known what direct effect these phosphorylation events
have on the PDH complex and its activity. In silico meth-
ods identified PKCζ or PKA as putative kinases responsi-
ble for phosphorylating the more acidic form and insulin
receptor kinase was identified for the more basic form.
Although little evidence connects PKCζ with the regula-
tion of cardiac energy metabolism, several reports have
established a role for PKCδ [34-36], with the loss of PKCδ
expression resulting in an increase in the ratio of lipid to
Table 1: Mass Spectrometry identification of protein spots using the Mascot Search Engine.
Protein Probability Based Mowse 
Score*
Peptides Sequence Identification and AC** (#)
Spot (#) Threshold Observed Matched Not matched Coverage
(P < 0.05) Score (n) (n) (%)
NADH-ubiquinone
1 58 141 17 41 44 oxidoreductase (24 kDa subunit),
P19234
Pyruvate dehydrogenase
23 21 0 8 3 3 11 0 ( β  E 1  s u b u n i t )
P49432
ATP synthase
3 58 127 13 40 34 (D subunit)
P31399
4 58 127 13 18 34 Long-chain acyl-CoA dehydrogenase
P15650
ATP synthase
55 8 8 7 1 2 2 84 1 ( α  s u b u n i t )
P15999
* -10 log(P) where P is the probability that the observed match is a random event.
**UniProtKB/Swiss-Prot primary accession number
Table 2: Mass Spectrometry identification of protein spots corresponding to the E1 subunit of PDH.
Protein Probability Based Mowse Score* Peptides Sequence Identification
Spot (#) Threshold Observed Matched Not matched Coverage
(P < 0.05) Score (n) (%)
1 Aerobic 32 108 3 31 10 Pyruvate dehydrogenase
(βE1 subunit)
2 Aerobic 69 167 21 5 59 Pyruvate dehydrogenase
(βE1 subunit)
1 I/R 31 85 2 40 13 Pyruvate dehydrogenase
(βE1 subunit)
2 I/R 69 151 21 13 59 Pyruvate dehydrogenase
(βE1 subunit)
* -10 log(P) where P is the probability that the observed match is a random event.Folmes et al. Proteome Science 2010, 8:38
http://www.proteomesci.com/content/8/1/38
Page 7 of 10
glucose metabolites and impaired cardioprotection due
to ischemic preconditioning [35,37]. Translocation of
PKCδ to the mitochondria results in differential expres-
sion of the PDH complex and the direct binding of PKCδ
to PDK2 can promotes phosphorylation-dependent inhi-
bition of PDH [34,36]. The present study would suggest
that PKC might also directly phosphorylate PDHE1β to
exert its effects on PDH activity. An alternative hypothe-
sis would be that phosphorylation at this site by PKA
stimulates PDH activity, as previous reports suggest that
treatment of isolated hearts with cAMP analogues or epi-
nephrine (which signals via cAMP) preferentially
increase glucose oxidation via an activation of PDH
[38,39]. The phosphorylation-induced activation of PDH
by insulin receptor kinase would also be consistent with
the activation of glucose oxidation by insulin [40].
Athough there is little evidence implicating insulin in
directly regulating PDH activity, there is some suggestion
that insulin may activate PDH phosphatase 2, leading to a
dephosphoryation and activation of PDH [41]. Five hours
of in vivo insulin infusion is sufficient to decrease mRNA
of PDK4, however it is unknown if this occurs with acute
insulin administration [42]. The identification of these
novel phosphorylation sites on PDHβE1 may have very
important implications on the regulation of PDH activity;
therefore further studies are required to determine the
ability of the putative kinases to phosphorylate these sites
in vitro and in vivo and their subsequent effect on PDH
activity.
The in silico analysis also identified a novel O-palmitoy-
lation PTM of the more acidic form of PDHβE1, which was
confirmed biochemically. To our knowledge this is the
first report of this modification in a mitochondrial pro-
tein. This finding may be of functional significance, as
only protein levels of the O-palmitoylated form of
PDHβE1 are decreased during I/R in the heart. Very few
studies have reported the existence of O-acylated pep-
tides, with one reporting that the removal of O-palmitoy-
lation from a threonine residue in the insect toxin PLTX-
II results in significant reduction in biological activity and
Figure 3 2-D electrophoresis identified two forms of the βE1 of 
pyruvate dehydrogenase (PDH). (A) Representative 2-D electropho-
resis of heart mitochondria indicating spots identified as βE1 subunit 
of PDH. (B) Quantification of spots identified as the βE1 of PDH pep-
tides and representative gels. Values represent the mean ± SEM of 3 
hearts per group. * represents P < 0.05, significantly different from aer-
obic value.
Figure 4 Protein mass fingerprints from aerobic heart mitochon-
dria showing the novel O-palmitoylation of the more acidic form 
of PDH. (A) PMFs of the more basic and more acidic forms of the βE1 
of PDH, and the PMF of the more acidic form of the βE1 after potassium 
hydroxide treatment (0.1M KOH room temperature for 4 hours). (B) Po-
tential site of O-palmitoylation of the more acidic form of βE1.Folmes et al. Proteome Science 2010, 8:38
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more recently an O-octanylation of a serine residue in
ghrelin was identified to be essential for its biological
activity [43,44]. Due to the scarcity of O-acylation of pep-
tides, no work has been performed on its biological role,
however much is known about the S- and N-palmitoyla-
tion of proteins [45]. These PTMs tend to promote both
membrane association of soluble proteins and targeting
of proteins to lipid rafts. As PDH is reported to be local-
ized to the inner mitochondrial membrane in cardiac tis-
sue [46], we hypothesize that palmitoylation of PDH
results in its recruitment to the inner mitochondrial
membrane, whereby it could interact with the monocar-
boxylate transport (the transporter required for pyruvate
entry into the mitochondria). In this case a reduction in
the palmitoylated form of PDH during I/R would result in
reduced inner mitochondrial membrane localization of
PDH, potentially reducing pyruvate flux and glucose oxi-
d a t i o n  i n  t h e  r e p e r f u s e d  h e a r t .  F u r t h e r  s t u d i e s  a r e
required to assess the effects of palmitoylation on PDH
activity, in order to determine its effects on glucose oxi-
dation in the ischemic heart.
A potential limitation of the present study is that our
global I/R protocol is mainly a model of myocardial stun-
Figure 5 Protein mass fingerprints of the more acidic form of PDH 
showing possible phosphorylation. (A) PMFs of the more acidic 
from of the βE1 of PDH from aerobic and I/R heart mitochondria and 
the PMF after alkaline phosphatase treatment (2 hrs at 30°C in 50 mM 
NH4HCO3). (B) Potential site of phosphorylation of the more acidic form 
of the βE1 of PDH.
Figure 6 Protein mass fingerprints of the more basic form of PDH 
showing possible phosphorylation. (A) PMFs of the more basic from 
of the βE1 of PDH from aerobic and I/R heart mitochondria and the 
PMF after alkaline phosphatase treatment (2 hr at 30°C in 50 mM 
NH4HCO3). (B) Potential site of phosphorylation of the more basic form 
of the βE1 of PDH.
Figure 7 Identification of putative kinases for the phosphoryla-
tion of the βE1 of PDH. (A) Graph showing the phosphorylation po-
tential of amino acids in the more basic form of the βE1 of PDH. (B) 
Isoelectric point of the more basic form of the βE1 of PDH. (C) Predict-
ed secondary structure surrounding the putative phosphorylation 
sites.Folmes et al. Proteome Science 2010, 8:38
http://www.proteomesci.com/content/8/1/38
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ning without significant necrosis and apoptosis, which
has limited clinical applicability. In addition, only subsar-
colemmal mitochondria were isolated using our protocol,
as nagarse was not included in our isolation buffer. This
protease was omitted because it has been demonstrated
that it affects the activity of NAD+ glycohydrolase and the
rate of NADH hydrolysis, which could potentially modify
other metabolic function [47,48]. To our knowledge no
one has examined the difference in the proteome of sub-
sarcolemmal and interfibrillar mitochondria, therefore it
is unknown how this would affect the interpretation of
the current data. Although we identified a number of
changes in mitochondrial protein abundance, the mecha-
nism by which I/R induces these changes is unknown, but
may include the release of mitochondrial proteins [8,49],
2) turnover of these proteins (balance between gene
expression/protein synthesis and protein degradation)
[50-52] and 3) post-translational modifications that sig-
nificantly change the pI or MW of the protein [6].
Conclusions
Using a functional proteomics approach we have identi-
fied novel changes in mitochondrial protein abundance
and PTMs of metabolic proteins in response to I/R. We
identified and partially characterized two molecular
forms of PDHβE1, which differ due to a novel O-palmitoy-
lation PTM. Also, for the first time we show that I/R
induces phosphorylation of PDHβE1, which is associated
with a decrease in glucose oxidation during reperfusion.
As PDH is the rate-limiting enzyme for glucose oxidation,
the regulation of these beta chain modifications may have
important implications on the regulation of glucose oxi-
dation in the heart.
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